DRTS Shows Promising Results Amidst Strong Stock Momentum
Recent updates from the REGAIN study indicate positive responses in glioblastoma treatments, with two patients achieving complete tumor disappearance. DRTS has shown remarkable stock performance, gaining 258.57% in the last year, making it a potentially attractive investment as it maintains bullish momentum technicals.
View signal analysis